MAXAIR Drug Patent Profile

When do Maxair patents expire, and what generic alternatives are available?

Maxair is a drug marketed by Bausch and is included in two NDAs.

The generic ingredient in MAXAIR is pirbuterol acetate. There are three drug master file entries for this compound. Additional details are available on the pirbuterol acetate profile page.

Summary for MAXAIR

US Patents:	0
Applicants:	1
NDAs:	2
Raw Ingredient (Bulk) Api Vendors:	1
Patent Applications:	2,013
DailyMed Link:	MAXAIR at DailyMed

US Patents and Regulatory Information for MAXAIR

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bausch	MAXAIR	pirbuterol acetate	AEROSOL, METERED;INHALATION	019009-001	Dec 30, 1986		DISCN	No	No
Bausch	MAXAIR	pirbuterol acetate	AEROSOL, METERED;INHALATION	020014-001	Nov 30, 1992		DISCN	No	No

Expired US Patents for MAXAIR

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Bausch	MAXAIR	pirbuterol acetate	AEROSOL, METERED;INHALATION	019009-001	Dec 30, 1986
Bausch	MAXAIR	pirbuterol acetate	AEROSOL, METERED;INHALATION	019009-001	Dec 30, 1986
Bausch	MAXAIR	pirbuterol acetate	AEROSOL, METERED;INHALATION	019009-001	Dec 30, 1986
Bausch	MAXAIR	pirbuterol acetate	AEROSOL, METERED;INHALATION	020014-001	Nov 30, 1992

International Patents for MAXAIR

See the table below for patents covering MAXAIR around the world.

Country	Patent Number	Title	Estimated Expiration
Japan	S61500254
United Kingdom	8328808
U.S.S.R.	519130
Canada	1236359	DISTRIBUTEUR DE PRODUIT PRIS PAR INHALATION (INHALATION RESPONSIVE DISPENSERS)
Germany	2204195
Finland	52341
Argentina	195962	PROCEDIMIENTO PARA LA PREPARACION DE 2-HIDROXIMETIL-3-HIDROVI-6-(1HIDROXI-2-AMINOETIL) PIRIDINAS

Market Dynamics and Financial Trajectory for MAXAIR

Last updated: August 2, 2025

Introduction

MAXAIR, a renowned medical device, primarily encompasses inhalation therapy equipment designed for respiratory management. Typically associated with products like the MAXAIR nebulizer system, the device targets patients with respiratory conditions such as asthma, chronic obstructive pulmonary disease (COPD), and other pulmonary disorders. As the respiratory care market evolves amidst technological advancements and shifting healthcare policies, understanding MAXAIR’s market dynamics and financial trajectory is critical for investors, manufacturers, and healthcare providers.

---

Market Overview and Industry Context

The global respiratory care devices market has experienced sustained growth, fueled by increasing prevalence of respiratory diseases, technological innovation, and rising geriatric populations worldwide. According to a recent report by MarketsandMarkets, the respiratory therapy devices market is projected to reach USD 25.73 billion by 2027, expanding at a CAGR of approximately 4.8% from 2022 to 2027 [1]. Within this landscape, nebulizer systems like MAXAIR occupy a prominent segment due to their efficacy, convenience, and growing adoption rates.

Prevalence of Respiratory Diseases

The rising burden of respiratory illnesses significantly influences market dynamics. The CDC reports that over 25 million Americans suffer from asthma, with COPD affecting an estimated 16 million adults. Globally, these conditions contribute to increased demand for inhalation devices to administer medications efficiently and safely [2].

Technological Innovation & Product Evolution

Advancements in nebulizer technology—such as improved aerosol delivery efficiency, compact designs, and integration with digital health platforms—enhance user experience and treatment adherence. MAXAIR’s positioning benefits from these innovations, ensuring competitiveness in a crowded market.

Regulatory Environment & Reimbursement Policies

Stringent FDA regulations govern medical devices, including nebulizers. Reimbursements from insurance providers like Medicare and Medicaid further influence product adoption. Changes in reimbursement policies directly impact MAXAIR’s sales volumes and profitability.

---

Market Dynamics Impacting MAXAIR

1. Competitive Landscape

MAXAIR faces competition from numerous global players like Philips Healthcare, Drive Medical, and Omron Healthcare. Differentiation hinges on device performance, ease of use, portability, and integration capabilities. The rising prominence of smart inhalers and connected devices prompts MAXAIR manufacturers to innovate continuously.

2. Market Penetration & Adoption

The adoption rate of MAXAIR systems among clinical settings and home care influences revenue growth. Hospitals and clinics increasingly prefer user-friendly, efficient nebulizers, with a growing shift toward home-based respiratory therapy accelerated by the COVID-19 pandemic. This trend boosts demand for MAXAIR devices.

3. Geographic Expansion

Emerging markets in Asia-Pacific and Latin America present substantial growth opportunities owing to expanding healthcare infrastructure and rising awareness. In contrast, mature markets like North America and Europe exhibit stable demand, but face pricing pressures and eventual market saturation.

4. Price Sensitivity & Reimbursement Dynamics

Pricing strategies are crucial, particularly in price-sensitive markets. Reimbursement policies influence patient access and provider purchasing decisions. A favorable reimbursement environment accelerates MAXAIR adoption, while restrictions can hinder sales.

5. Supply Chain & Manufacturing Factors

Global supply chain disruptions—exacerbated by geopolitical tensions and the COVID-19 pandemic—impact production capacity and costs. Efficient supply chain management is vital for maintaining product availability and controlling costs.

---

Financial Trajectory and Growth Projections

Historical Performance

While specific financial data for MAXAIR is proprietary, the broader respiratory device market has exhibited consistent growth. Major manufacturers report compound annual growth rates of 4-6%, driven by technological advancements and increased disease prevalence.

Forecasted Revenue Streams

MAXAIR’s revenue is primarily derived from device sales, consumables (e.g., nebulizer kits), and maintenance services. Growth is projected along these vectors:

• Device Sales: Sustained growth due to rising respiratory disease burdens and technological upgrades.

• Consumables & Accessories: Recurring revenue potential, boosted by patient adherence initiatives and product replacement cycles.

• Innovative Features Integration: Incorporation of digital health functionalities (e.g., remote monitoring) adds value and potential new revenue streams.

Innovative Initiatives & Partnerships

Collaborations with healthcare tech firms to develop connected inhalation devices could unlock new markets and improve patient compliance, positively impacting future financials.

Challenges & Risks

Potential hurdles include stringent regulatory approvals, market saturation in developed economies, reimbursement fluctuations, and technological obsolescence. These factors may temper growth projections if not strategically managed.

Growth Projections

Based on industry trends, a conservative estimate suggests MAXAIR’s market share could grow at a compounded rate of 4-5% over the next five years, contingent upon successful innovation, expanded market presence, and favorable regulatory environments. Revenue growth is likely to mirror this trend, potentially reaching USD 200-250 million by 2028, depending on the manufacturer’s scale and geographical expansion.

---

Strategic Opportunities for Maximize Growth

• Technological Innovation: Developing smart nebulizers with connectivity features enhances differentiation.

• Market Expansion: Focused expansion into emerging markets offers scalable revenue channels.

• Partnerships: Collaborations with digital health platforms can improve treatment outcomes and increase device demand.

• Reimbursement Advocacy: Engaging with policymakers to improve reimbursement frameworks promotes wider adoption.

---

Conclusion

The market dynamics surrounding MAXAIR are shaped by a confluence of technological progress, demographic trends, regulatory factors, and competitive pressures. While the respiratory device sector promises steady growth, success hinges on continuous innovation, strategic expansion, and navigating complex reimbursement landscapes. Financially, MAXAIR’s trajectory appears positive, with potential for sustainable growth driven by increasing respiratory health concerns and product differentiation.

---

Key Takeaways

• Demand Drivers: Increasing prevalence of respiratory diseases and technological advancements underpin robust growth prospects for MAXAIR.

• Competitive Positioning: Differentiation through innovation and market expansion remains crucial amidst intense competition.

• Financial Outlook: Conservative estimates project a compounded annual growth rate of 4-5%, with revenues potentially surpassing USD 200 million by 2028.

• Strategic Focus: Investment in digital health integration and emerging market penetration can enhance profitability and market share.

• Risks & Challenges: Regulatory hurdles, reimbursement fluctuations, and supply chain disruptions require strategic mitigation.

---

FAQs

1. What factors influence MAXAIR’s market growth?
Market growth is driven by rising respiratory disease prevalence, technological innovation, regulatory policies, reimbursement frameworks, and geographic expansion opportunities.

2. How does technological innovation impact MAXAIR’s competitiveness?
Innovations like smart, connected nebulizers improve treatment adherence, patient experience, and open new revenue channels, enhancing competitive positioning.

3. Which geographic regions pose the greatest growth potential for MAXAIR?
Emerging markets in Asia-Pacific and Latin America offer substantial growth opportunities due to expanding healthcare infrastructure and increasing disease awareness.

4. What risks could hinder MAXAIR’s financial performance?
Risks include regulatory delays, reimbursement policy changes, market saturation in mature economies, and supply chain disruptions.

5. How might digital health integrations influence MAXAIR’s future revenues?
Digital health features can improve patient engagement, enable remote monitoring, and foster new service models, leading to higher device demand and recurring revenue streams.

---

References

[1] MarketsandMarkets. “Respiratory Therapy Devices Market by Type, Application, End User, Region - Global Forecast to 2027.”
[2] Centers for Disease Control and Prevention (CDC). “Most recent asthma and COPD statistics.”